Ranbaxy strikes deal with Scigen

By siliconindia staff writer   |   Thursday, 19 August 2004, 07:00 Hrs
Printer Print Email Email
NEW DELHI: Ranbaxy is set to make a big-bang entry into the fast-growing domestic insulin market with an imported product.

The pharma major has struck a deal with Singapore-based Scigen for marketing its insulin product in India.

While details of the Ranbaxy-Scigen deal are kept under wraps, sources said Ranbaxy is planning to position the product differently to make an early impact in the market, currently dominated by two multinationals — Novo Nordisk and Eli Lilly.

Ranbaxy’s move to enter the insulin market is in line with the company’s strategy to reinforce its presence in high-growth therapeutic categories. The insulin market is currently growing at a healthy 25%. The company would gradually be reducing its reliance on segments like anti-infectives, which has seen major de-growth.

According to an IMS world-wide survey, more than 135m diabetes cases exist in the world today, and this is expected to rise to 300m by 2025. The anti-diabetes market is expected to cross $20bn by ’06.

Currently, there are only a few players — Novo Nordisk, Eli Lilly, USV, Aventis and Wockhardt — in the Rs 300 crore domestic insulin market. Novo and Lilly command about 80-85% of the market. The last round of price cut on human insulin, the steepest ever, was initiated by Lilly in January ’02.

SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..